FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2981612046> ?p ?o ?g. }

• W2981612046 endingPage "S784" @default.
• W2981612046 startingPage "S783" @default.
• W2981612046 abstract "Abstract Background Avibactam (AVI) is a β-lactamase inhibitor with potent inhibitory activity against Class A, Class C, and some Class D serine β-lactamases. The combination of ceftazidime (CAZ) with AVI has been approved in Europe and in the United States for several indications. This study evaluated the in vitro activity of CAZ-AVI and comparators against Enterobacterales (Eba) and Pseudomonas aeruginosa (Pae) isolates collected from patients with bloodstream infections as part of the ATLAS surveillance program in 2015-2018. Methods A total of 57048 Eba and 15813 Pae non-duplicate clinically significant isolates, including 7720 Eba and 1286 Pae isolated from bloodstream infections, were collected in 52 countries in Europe, Latin America, Asia/Pacific (excluding mainland China), and the Middle East/Africa region. Susceptibility testing was performed by CLSI broth microdilution. CAZ-AVI was tested at a fixed concentration of 4 µg/ml AVI. Meropenem-nonsusceptible (MEM-NS) Eba and Pae isolates were screened for the presence of β-lactamase genes. Results Susceptibility data are shown in the Table. Percentages of susceptibility (% S) to the tested agents were 0.3-2.9% lower among Eba and Pae from bloodstream infections compared to isolates from combined sources in most cases. CAZ-AVI showed potent in vitro activity against all Eba bloodstream isolates and the CAZ-NS subset (MIC90, 0.5-2 µg/ml, 93.4-98.1% S). Reduced activity against MEM-NS Eba was attributable to carriage of class B metallo-β-lactamases (MBLs) because 99% of MEM-NS MBL-negative isolates were susceptible to CAZ-AVI. None of the tested comparators exceeded the activity of CAZ-AVI. CAZ-AVI also showed good in vitro activity against the majority of Pae bloodstream isolates (MIC90, 16 µg/ml, 89.4% S). Activity was reduced against CAZ-NS and MEM-NS subsets (54.2-63.8% S), which included isolates carrying MBLs, but exceeded the activity of CAZ and MEM against these subsets by 26-31 percentage points. Amikacin was the only tested comparator that demonstrated comparable activity against Pae bloodstream isolates. Table Conclusion CAZ-AVI provides a valuable therapeutic option for treating bloodstream infections caused by MBL-negative Eba and Pae isolates. Disclosures Krystyna Kazmierczak, PhD, IHMA (Employee)Pfizer, Inc. (Consultant) Sibylle Lob, PhD, IHMA (Employee)Pfizer, Inc. (Consultant) Greg Stone, PhD, AztraZeneca (Shareholder, Former Employee)Pfizer, Inc. (Employee) Daniel F. Sahm, PhD, IHMA (Employee)Pfizer, Inc. (Consultant)Shionogi & Co., Ltd. (Independent Contractor)" @default.
• W2981612046 created "2019-11-01" @default.
• W2981612046 creator A5015415938 @default.
• W2981612046 creator A5017159626 @default.
• W2981612046 creator A5038009031 @default.
• W2981612046 creator A5066677972 @default.
• W2981612046 date "2020-10-01" @default.
• W2981612046 modified "2023-09-23" @default.
• W2981612046 title "1569. In Vitro Activity of Ceftazidime-avibactam and Comparator Agents against Enterobacterales and Pseudomonas aeruginosa Collected from Patients with Bloodstream Infections as Part of the ATLAS Global Surveillance Program, 2015-2018" @default.
• W2981612046 doi "https://doi.org/10.1093/ofid/ofaa439.1749" @default.
• W2981612046 hasPublicationYear "2020" @default.
• W2981612046 type Work @default.
• W2981612046 sameAs 2981612046 @default.
• W2981612046 citedByCount "0" @default.
• W2981612046 crossrefType "journal-article" @default.
• W2981612046 hasAuthorship W2981612046A5015415938 @default.
• W2981612046 hasAuthorship W2981612046A5017159626 @default.
• W2981612046 hasAuthorship W2981612046A5038009031 @default.
• W2981612046 hasAuthorship W2981612046A5066677972 @default.
• W2981612046 hasBestOaLocation W29816120461 @default.
• W2981612046 hasConcept C176947019 @default.
• W2981612046 hasConcept C2775933652 @default.
• W2981612046 hasConcept C2776968632 @default.
• W2981612046 hasConcept C2777406300 @default.
• W2981612046 hasConcept C2777637488 @default.
• W2981612046 hasConcept C2780950330 @default.
• W2981612046 hasConcept C501593827 @default.
• W2981612046 hasConcept C523546767 @default.
• W2981612046 hasConcept C54355233 @default.
• W2981612046 hasConcept C71924100 @default.
• W2981612046 hasConcept C86803240 @default.
• W2981612046 hasConcept C89423630 @default.
• W2981612046 hasConceptScore W2981612046C176947019 @default.
• W2981612046 hasConceptScore W2981612046C2775933652 @default.
• W2981612046 hasConceptScore W2981612046C2776968632 @default.
• W2981612046 hasConceptScore W2981612046C2777406300 @default.
• W2981612046 hasConceptScore W2981612046C2777637488 @default.
• W2981612046 hasConceptScore W2981612046C2780950330 @default.
• W2981612046 hasConceptScore W2981612046C501593827 @default.
• W2981612046 hasConceptScore W2981612046C523546767 @default.
• W2981612046 hasConceptScore W2981612046C54355233 @default.
• W2981612046 hasConceptScore W2981612046C71924100 @default.
• W2981612046 hasConceptScore W2981612046C86803240 @default.
• W2981612046 hasConceptScore W2981612046C89423630 @default.
• W2981612046 hasIssue "Supplement_1" @default.
• W2981612046 hasLocation W29816120461 @default.
• W2981612046 hasLocation W29816120462 @default.
• W2981612046 hasLocation W29816120463 @default.
• W2981612046 hasOpenAccess W2981612046 @default.
• W2981612046 hasPrimaryLocation W29816120461 @default.
• W2981612046 hasRelatedWork W1524642279 @default.
• W2981612046 hasRelatedWork W2261913017 @default.
• W2981612046 hasRelatedWork W2901057130 @default.
• W2981612046 hasRelatedWork W2946700181 @default.
• W2981612046 hasRelatedWork W3027419335 @default.
• W2981612046 hasRelatedWork W3119311612 @default.
• W2981612046 hasRelatedWork W4224302300 @default.
• W2981612046 hasRelatedWork W4310676567 @default.
• W2981612046 hasRelatedWork W4319295365 @default.
• W2981612046 hasRelatedWork W4321189322 @default.
• W2981612046 hasVolume "7" @default.
• W2981612046 isParatext "false" @default.
• W2981612046 isRetracted "false" @default.
• W2981612046 magId "2981612046" @default.
• W2981612046 workType "article" @default.